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ABSTRACT: Liquid chromatography tandem mass spectrometry
(LC−MS/MS) based methods provide powerful tools for the
quantitative analysis of modiﬁed proteins. We have developed a
label-free approach using internal reference peptides (IRP) from the
target protein for signal normalization without the need for isotope
labeling. Ion-trap mass spectrometry and pseudo-selected reaction
monitoring (pSRM) were used to acquire full MS/MS and MS3
spectra from target peptides. Skyline, a widely used software for SRM
experiments, was used for chromatographic ion extraction. Phospho-
peptides spiked into a BSA background yielded concentration
response curves with high correlation coeﬃcients (typically >0.9)
and low coeﬃcients of variation (≤15%) over a 200-fold concentration range. Stable isotope dilution (SID) and IRP methods
were compared for quantitation of six site-speciﬁc phosphorylations in the epidermal growth factor receptor (EGFR) in
epidermal growth factor-stimulated A431 cells with or without the addition of EGFR inhibitors cetuximab and geﬁtinib.
Equivalent responses were observed with both IRP and SID methods, although analyses using the IRP method typically had
higher median CVs (22−31%) than SID (10−20%). Analyses using both methods were consistent with immunoblot using site-
selective antibodies. The ease of implementation and the suitability for targeted quantitative comparisons make this method
suitable for broad application in protein biochemistry.
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■ INTRODUCTION
Posttranslational protein modiﬁcations (PTM), such as
phosphorylation, are diﬃcult to quantify because they are
highly dynamic, present on proteins at low levels, and often of
low stoichiometries. Quantitative analysis of PTM has been
achieved using liquid chromatography tandem mass spectrom-
etry (LC−MS/MS).
1−4 Global quantiﬁcation of phosphoryla-
tion or other PTM typically employs isotope labeling by
chemical derivatization (e.g., iTRAQ) or metabolic incorpo-
ration of stable isotope-labeled amino acids in cell culture
(SILAC).
5−8 Stable isotope dilution provides the highest
precision for quantitative MS studies;
7−9 however, it requires
both synthesis and amino acid analysis for each peptide of
interest. The cost associated with SID quanatitive analyses
becomes cost-prohibitive when many targets need to be
analyzed.
An alternative to stable isotope labeling strategies is the use
of commonly performed and accepted “label free” quantitation
methods. These methods fall broadly into two groups, spectral
counting and integrating MS1 peak areas. Although spectral
counting methods compares favorably to stable isotope labeling
in both precision and accuracy for quantifying proteins in
shotgun proteomics analyses,
10,11 the sampling of individual
modiﬁed peptide spectra by “data-dependent MS/MS” is
insuﬃcient in capturing enough spectra to use this method
for quantiﬁcation at the peptide level. Quantiﬁcation by
integrated MS1 signals for speciﬁc peptide ions is performed
by extraction of selected ion chromatograms from LC−MS data
sets.
12−14 Although a higher resolution instrument, such as an
LTQ-Orbitrap or Q-TOF, may improve the background for an
MS1 signal, this instrumentation may not be readily available for
these experiments. In addition, the MS1 signal does not
distinguish between sites of diﬀerentially modiﬁed peptides,
particularly problematic when the peptides cannot be
chromatographically resolved, and MS1 signals for lower level
peptides (such as modiﬁed peptiedes) are frequently hindered
because of signiﬁcant background noise. Ion traps also have the
ability to perform MS3, which is not possible with Q-TOF
intruments. In many cases, analysis of PTM is done on puriﬁed
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expressed proteins, or proteins puriﬁed by chromatography or
electrophoresis. In such cases, the need to quantify a
stoichiometric change in a modiﬁcation frequently follows the
initial identiﬁcation of modiﬁed forms. Since the modiﬁed form
has been identiﬁed, the MS/MS spectral characteristics of the
modiﬁed peptides of interest are known. In this context, the
goal is targeted quantitation of changes to speciﬁc proteins,
rather than a quantitative global survey. Here we describe the
validation of a label-free approach to measure quantitative
changes in modiﬁcations to speciﬁc proteins. The approach
uses targeted LC−MS/MS analysis with extracted selected
reaction monitoring (pseudo-SRM or pSRM) using a linear
ion-trap mass spectrometer to enable selective detection and
further quantiﬁcation of modiﬁed peptides. We have
implemented full support for this workﬂow in version 1.1 of
the software tool Skyline (http://proteome.gs.washington.edu/
software/skyline/), a widely used, freely available tool for SRM
anlaysis.
15 To correct for run-to-run variations in signal
intensities, pSRM signals for the target peptides are normalized
to signals from unmodiﬁed reference peptides from the same
protein, which we termed the internal reference peptide (IRP)
method. Although we and others have described similar
quantiﬁcation methods previously,
12,16−23 here we performed
proof-of-principle experiments that allowed us to validate the
method, deﬁne its performance characteristics and compare
them to stable isotope dilution, which is the accepted “gold
standard” for SRM-based quantitation. We further assessed the
performance of pSRM using both MS/MS and MS3 data for
quantiﬁcation. We describe the application of the IRP method
to analyze phosphorylated forms of epidermal growth factor
receptor (EGFR), an extensively characterized receptor
tyrosine kinase and a target for several clinically used anticancer
drugs. Our data demonstrate the proﬁciency of the IRP method
to quantify site-speciﬁc changes in EGFR phosphorylation in
response to modulation by EGF and the two tyrosine kinase
inhibitors, cetuximab and geﬁtinib.
■ EXPERIMENTAL PROCEDURES
Materials and Reagents
Acetonitrile and HPLC-grade water were from Mallinckrodt
Baker (Phillipsburg, NJ), and 98% pure formic acid was from
EMD (Darmstadt, Germany). Trypsin gold was purchased
from Promega (Madison, WI), dithiothreitol (DTT) from
Pierce (Rockford, IL), and iodacetamide was from Sigma (St.
Louis, MO). The A431 cell line was obtained from ATCC
(Manassas, VA), improved MEM media, and PBS were
purchased from Invitrogen-GIBCO (Auckland, NZ). Media
supplement, fetal bovine serum, was from Atlas Biologicals
(Fort Collins, CO). For Western blotting, primary antibodies
forphosphotyrosine site 1172, phosphotyrosine site 998 and
EGFR were purchased from Cell Signaling Technology
(Danvers, MA). Primary antibodies were detected using
antirabbit and antimouse secondary antibodies conjugated
with Fluorophore 680 from Invitrogen (Carlsbad, CA) and
imaged using the LI-COR Odyssey Imager system with 3.0
application software (Lincoln, NE). All gels (NuPAGE),
Western blot membranes and gel reagents (LDS, PVDF
membrane, and SimplyBlue SafeStain) were purchased from
Invitrogen (Carlsbad, CA). Individual components of the
NETN lysis buﬀer, protease inhibitor cocktail and phosphatase
inhibitor cocktail (see below) were purchased from Sigma (St.
Louis, MO). Beads for immunoprecipitations, Protein A and
Protein G were purchased from ThermoScientiﬁc (Rockford,
IL) and Roche (Indianapolis, IN), respectively.
Synthetic phosphorylated peptides, DRVpYIHPF and
IKNLQpSLDPSH, were purchased as part of the Phosphopep-
tide Standard I from Protea Biosciences (Morgantown, WV).
Bovine serum albumin (BSA) was purchased from Thermo-
Scientiﬁc (Rockford, IL). Four C-terminal isotopically labeled
phosphotyrosine peptides containing U−13C6,U −15N4-arginine
or U−13C6,U −15N2-lysine from EGFR (Y998−
MHLPSPTDSNFpYR, Y1110−RPAGSVQNPVpYHNQPLN-
PAPSR, Y1172−GSHQISLDNPDpYQQDFFPK, and Y1197−
GSTAENAEpYLR) were purchased from New England
Peptide, LLC (Gardner, MA) at ≥95% chemical purity based
on amino acid analysis. EGFR antibody and cetuximab were a
gift from Dr. Robert Coﬀey; geﬁtinib was a gift from Dr. Carlos
Arteaga, both from Vanderbilt−Ingram Cancer Center (Nash-
ville, TN).
Phosphopeptide/BSA Spike Experiments
Synthetic phosphopeptide mixture (DRVpYIHPF and
IKNLQpSLDPSH) was resuspended in 0.1% formic acid to a
concentration of 500 pmol mL−1, and peptides were spiked into
100 μL of 6.0 μgm L −1 (6 ng of BSA) tryptic digest of BSA at
concentrations ranging from 0.01 to 2.0 fmol ng−1 of BSA
(which corresponds to 0.064−12.8 fmol μL−1) in 0.1% formic
acid. The BSA tryptic digest was performed on 200 μgo f2m g
mL−1 o fB S A .T h es a m p l ew a sd i l u t e di na m m o n i u m
bicarbonate, reduced in 45 mM DTT at 55 °C for 20 min,
alkylated in the dark at room temperature for 20 min using 100
mM iodoacetamide, and digested with 4 μg of trypsin overnight
at 37 °C. An aliquot of this digest was diluted with 0.1% formic
acid to a ﬁnal concentration of 6.0 μgm L −1.
Cell Culture
A human epithelial carcinoma cell line (A431) was cultured in
150 mm culture dishes in improved MEM supplemented with
10% fetal bovine serum at 37 °Ci n5 %C O 2. A431 cells were
grown to ∼60−70% conﬂuency prior to harvesting (control or
treatment). All treated cells were serum-starved (18 h),
followed by treatment with 30 nmol epidermal growth factor
(EGF) for 20 min or incubated with either 10 μgm L −1
cetuximab or 500 nmol geﬁtinib for 30 min followed by
subsequent stimulation with EGF for 20 min. Cells were
harvested on ice with Mg and Cl-free PBS supplemented with a
phosphatase inhibitor cocktail (1 mM sodium ﬂuoride, 10 mM
β-glycerophosphate, 1 mM sodium molybdate, and 1 mM
activated sodium orthovanadate), pelleted by centrifugation at
∼250g, ﬂash-frozen, and stored at −80 °C.
Immunoprecipitation, Western Blot, and Sample
Preparation
Cell pellets were lysed by resuspension in NETN lysis buﬀer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Igepal, and 5%
glycerol) containing protease inhibitors (0.5 mM 4-(2-
aminoethyl)benzenesulfonyl ﬂuoride hydrochloride, 10 mM
aprotinin, 1 mM leupeptin, 1.5 μM E-64, 5 μM betastatin, and
1 μM pepstatin A) and the phosphatase inhibitor cocktail and
incubated on ice for 25 min prior to mechanical lysis by
sonication. After cell lysis, suspensions were cleared by
centrifugation at 9400g for 5 min. The bicinchoninic acid
assay (protein standard was bovine serum albumin) was used to
measure the protein concentration of the cell lysate. A 100 μg
aliquot of total cell lysate was collected as input control and
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concentration of 1X and 50 mM, respectively. A 3 mg portion
of the remaining cleared lysate was incubated at 4 °C for 1.5 h
with cetuximab at a ratio of 5 μg of cetuximab for every 1 mg of
cell lysate. A 30 μL portion of pre-equilibrated protein A and
protein G resin (1:1 v/v) was added to the suspension and
incubated with the lysate for 45 min at 4 °C. The suspension
was then centrifuged at ∼200g for 2 min at 4 °C. The
supernatant was removed and the resin washed three times with
NETN lysis buﬀer. Protein(s) were eluted by treating beads for
5 min at 85 °C in 2X LDS buﬀer and 50 mM DTT. Samples
were fractionated in NuPAGE 10% Bis-Tris SDS−PAGE gels
using MOPS buﬀer. Gels were either prepared for Western blot
by transferring proteins to PVDF membrane or stained (for 1
h) using SimplyBlue SafeStain followed by destaining in
deionized water overnight.
Targeted MS analysis was performed on the digested EGFR
gel regions. Brieﬂy, the EGFR protein bands were excised and
rinsed with 100 mM ammonium bicarbonate (pH 8.0). Gel
pieces were reduced with 50 mM DTT at 60 °C for 30 min,
followed by alkylation with 100 mM iodoacetamide in the dark
at ambient temperature for 20 min, and digested with 200 ng
trypsin overnight at 37 °C. Peptides were extracted from the gel
three times with 60% acetonitrile/0.1% formic acid (v/v).
Peptides were concentrated in vacuo (SpeedVac concentrator,
Thermo-Fisher, Waltham, WA) and reconstituted in 30 μLo f
5% acetonitrile and 0.1% formic acid with 12.5 fmol μL−1 of
isotopically labeled peptides spiked in for LC−pSRM−MS
analysis.
Mass Spectrometry and Data Analyses
LC−pSRM−MS and MSn analyses were performed on a
ThermoFisher LTQ Velos (San Jose, CA) mass spectrometer
equipped with an Eksigent Nano-1D Plus HPLC and AS-1
autosampler (Dublin, CA). Peptides were separated on a 100
μm × 11 cm fused silica capillary column (Polymicro
Technologies, LLC., Phoenix, AZ) and 100 μm × 6 cm fused
silica capillary precolumn packed with 5 μm, 300 Å Jupiter C18
(Phenomenex, Torrance, CA). Liquid chromatography was
performed using a 95 min gradient at a ﬂow rate of either 400
or 600 nL min−1 using a gradient mixture of 0.1% (v/v) formic
acid in water (solvent A) and 0.1% (v/v) formic acid in
acetonitrile (solvent B). Brieﬂy, a 15 min wash period (100%
Figure 6. Skyline display from replicate peak areas and imported targeted MS/MS data to produce pSRM traces for GSTAENAEpYLR from A431
cells not treated (proliferating), modulated with EGF, or cotreated with inhibitor (cetuximab or geﬁtinib) followed by EGF. Samples were acquired
using a Thermo Fisher LTQ-Velos. Replicate peak areas show the reproducibility of the peaks and their composition from the pSRM traces.
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15 min (1.2 μL min−1), and eluent was diverted to waste prior
to the analytical column using a vented column set up similar to
that previously described.
24 Following removal of residual salts,
the ﬂow was redirected to ﬂow through the analytical column
and solvent B increased to 75% over 35 min and up to 90% in
65 min. The column was re-equlibrated to 98% solvent A for 10
min after each run. All peptides were analyzed using targeted
analysis of doubly and/or triply charged ions to acquire the
complete MS/MS spectrum. MS3 analysis was performed on
the neutral loss of phosphoric acid for phosphopeptides
IKNLQpSLDPSH (Protea peptide), MHLPpSPTDSNYR, and
GSHQIpSLDNPDYQQDFFPK (both EGFR phosphopepti-
des) in addition to MS/MS analysis. Typical targeted
parameters include an isolation width of two bracketed around
the m/z of interest, a fragmentation time of 10 ms, normalized
collision energy of 35.0, spray voltage of 1.8 kV, and capillary
temperature at 200 °C.
Data was analyzed using either Xcalibur software (Thermo-
Fisher, San Jose, CA) to determine extracted ion current peak
area for 3−5 transitions for each targeted peptide or the full
scan MS/MS ﬁltering feature in Skyline 1.1 software.
15 Each
phosphopeptide was normalized by dividing the individual
phosphopeptide (sum of three or four ion transitions/peptide)
by either the individual reference peptides (sum of three or four
ion transitions/peptide) or the sum of all of the references
(unmodiﬁed internal peptides from BSA or EGFR) peptides.
Skyline Implementation
Full support for pSRM using chromatograms extracted from
targeted MS/MS spectra for peak area calculations was
implemented in the Skyline software tool, as shown in Figures
2, 6 and S1 (Supporting Information), and released in version
1.1. These new features included method export for Thermo-
Fisher LTQ instruments as well as chromatogram extraction
from MS/MS spectra at targeted product ion mass-to-charge
ratios, making available for pSRM many existing Skyline
features proven in SRM experiments with triple quadrupole
mass spectrometers.
Statistical Methods
The relationship between response and concentration was
modeled by applying a weighted least-squares with the robust
linear model using Tukey’s biweight to down-weight potential
outliers. This model
25 assumes that measurement standard
deviation increases linearly with concentration. The model also
accounts for nonlinear behavior at low concentrations by
incorporating change-points. Selection of change points is
based on Akaike’s information criterion (AIC), where the
optimal model is the one with the minimum AIC. The ﬁtted
model provided three summary statistics: correlation coeﬃcient
(r2), slope, and coeﬃcient of variation (CV). The details of the
methods have been described previously.
8,25
■ RESULTS
Overview of Analytical Approach
This work describes quantitative analysis of post-translationally
modiﬁed (PTM) peptides by pSRM together with either stable
isotope dilution (SID) or a new IRP method. The pSRM
experiments are targeted MS/MS analyses performed by
producing a full MS/MS spectrum for each precursor m/z in
a target list using a linear ion trap mass spectrometer (LTQ
Velos). Transitions are extracted from the full MS/MS or MS3
spectrum and peak areas for transitions are summed and
normalized to areas for a reference standard. For stable-isotope
dilution (SID), the summed peak area is normalized to
summed peak areas for transitions from a stable isotope labeled
peptide standard. In the IRP method, one or more unmodiﬁed
proteotypic peptides from the target protein serve as the
reference standard for the modiﬁed peptides in the analysis.
Because the target modiﬁed peptides and the reference
standard are present in the same protein, the IRP method
corrects for variations in recovery of the protein in the analysis.
Normalized signals increase or decrease with a corresponding
increase or decrease in the stoichiometry of the modiﬁcation.
Analyses of Phosphopeptides Spiked into a BSA Digest
To test the ability of the IRP method to detect diﬀerences in
modiﬁcation stoichiometry as changes in normalized pSRM
ratio, we performed proof-of-principle experiments by spiking
synthetic phosphopeptides into a BSA background (see Figure
1). The peptides, DRVpYIHPF (angiotensin II) and
IKNLQpSLDPSH (cholecystokinin 10−20), were spiked into
100 μLo f6μgm L −1 BSA digest at 0.01, 0.02, 0.05, 0.10, 0.20,
0.50, 1.0, and 2.0 fmol ng−1 BSA. These concentrations were
chosen to mimic the low abundance phosphorylation events
that occur in biological systems;
12 these spike concentrations
correlated to 0.12−14% stoichiometry relative to BSA.
Concentration−response curves were generated by analyzing
each concentration point (ﬁve replicate LC−MS injections) on
an LTQ Velos linear ion trap using pSRM. For each spiked
peptide, extracted ion chromatograms (XICs) for three to four
transitions were chosen based on stability (low variability in
peak area), sequence, or modiﬁcation-speciﬁc transitions (when
Figure 1. Internal reference peptide proof-of-principle experiment.
Synthetic phosphopeptides were spiked into a standard bovine serum
albumin (BSA) protein digest at increasing concentrations (0.064−
12.8 fmol μL−1). Phosphorylated peptides were targeted employing
pSRM using a linear ion-trap mass spectrometer. Data is normalized
by dividing targeted phosphorylated peptide peak area (sum of three
to four transitions) by BSA peptide peak areas (sum of three
transitions).
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MS1 and product ion ﬁltering feature in Skyline showing
chromatographic proﬁles for the high (2.0 fmol ng−1 BSA) and
low (0.02 fmol ng−1 BSA) concentration of phosphorylated
peptide spiked into BSA. This ﬁgure clearly demonstrates the
advantage of the pSRM over MS1 signal extraction to quantify
at lower concentrations due to the increased speciﬁcity leading
to a greater signal-to-noise. We also acquired these data using
an LTQ-Orbitrap with the tandem MS collected on the LTQ
portion of the experiment and the MS1 collected in the
Orbitrap portion of the instrument. The MS1 signal in the
Orbitrap was signiﬁcantly improved in the Orbitrap and the
Figure 2. Skyline display from replicate peak areas and imported targeted full MS and MS/MS data from a high (2.0 fmol ng−1 BSA), medium (0.2
fmol ng−1 BSA), and low (0.02 fmol ng−1 BSA) concentration of a phosphorylated peptide (DRVpYIHPF) spiked into BSA. Samples were run on a
Thermo Fisher LTQ-Velos, low-resolution instrument. The precursor ion, in blue, is ﬁltered from MS1 scans taken at the beginning of each cycle. At
lower concentrations, interference becomes an issue for the precursor in the MS1 scans; however, the ﬁltered product ions from the targeted MS/MS
remain selective and free from interference producing a clear chromatographic peak. Replicate peak areas show the reproducibility of the peaks and
their composition from the fragment ion (tandem MS) traces.
Figure 3. Median CV across technical replicates plotted against amount of spiked in phosphorylated peptide standards. Data point colors correspond
to reference peptide used for normalization. The median CVs decrease as the amount of phosphopeptide spiked in background (BSA digest)
increases.
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peptide sequences, precursor m/z and speciﬁc transitions
extracted are listed in Table S41 (Supporting Information).
The sum of transition peak areas for phosphopeptides was
divided either by (a) the sum of transition peak areas for
individual reference BSA peptides or by (b) the sum of the
transition peak areas for all reference BSA peptides. To assess
the ability to use MS3 measurements for quantiﬁcation of
protein modiﬁcations, MS3 of the neutral loss ion [M + 3H −
H3PO4]3+ of phosphopeptide IKNLQpSLDPSH was also
measured.
MS/MS and MS3 data from ﬁve replicate LC−MS analyses
of BSA digests spiked with both phosphopeptides were
normalized by the IRP method and concentration response
curves are shown in Figure S3 (Supporting Information).
Concentration−response curve slopes, correlation coeﬃcients
(r2), and coeﬃcients of variation (CV) for all reference peptides
are presented in Table 1. Individual plots for all of the
measured peptides are shown in Figures S5−S7 (Supporting
Information) and plots of the median CVs for all replicates are
in Figure 3. Despite the fact that all of the normalization
peptides were derived from an equal amount of BSA in the
sample, values for r2, slope, and CV for normalization varied.
CV values ranged from 7.3 to 15.7% (median 10%). The the
utilization of the BSA reference peptide YICDNQDTISSK for
quantation of the phosphorylated peptides yielded the highest
r2 values (≥0.96), lowest slope, and lowest median CV
(≤10.8%) compared to the other reference peptides. Similar
values for r2, slope, and CV were obtained for both MS/MS and
MS3 measurements. The highest median CV was observed at
the lowest phosphopeptide spike amount (0.128 fmol) for both
phosphopeptides (MS/MS and MS3 data; Figure 3, Supporting
Information). Plots derived using single BSA reference peptides
and using the sum of all BSA reference peptides are presented
in Figures S8−S10 (Supporting Information). These experi-
ments were performed on a linear ion trap with automatic gain
control (AGC), which limits ﬁlling of the trap at higher ion
currents, thus potentially limiting linear dynamic range. In these
studies, IRP-normalized signals appeared linear over the 200-
fold concentration range examined, which suggests that AGC
has little impact on response under the conditions of our
analyses.
Comparison of IRP Method and SID-Based Quantitation of
Site-Speciﬁc Phosphorylation in EGFR
To evaluate the performance of the IRP method for relative
quantiﬁcation of speciﬁc protein phosphorylation sites, we
examined the changes in phosphorylation levels in EGFR
regulated by EGF stimulation and inhibition. An EGFR
overexpressing human epithelial carcinoma cell line, A431,
was harvested (1) prior to any cell treatment (proliferating
cells), (2) after serum starvation overnight and stimulation with
EGF, (3) after cotreatment with 10 μgm L −1 cetuximab
(monoclonal antibody inhibitor of EGFR) and EGF, and (4)
after cotreatment with 500 nM geﬁtinib (small molecule EGFR
tyrosine kinase inhibitor) and EGF.
Immunoblot analyses were performed pre- and post IP for
each treatment group for total EGFR and speciﬁc pY sites Y998
and Y1172. EGFR speciﬁc pY sites Y998 and Y1172 were
chosen for immunoblot analysis because both sites have high-
quality, commercially available site-speciﬁc antibodies. Phos-
phorylation at both residues has been linked to pertinent EGFR
biology with Y998 representing a phosphorylation site
implicated in receptor endocytosis and Y1172 representing a
site of autophosphorylation. The purpose of these studies was
not to produce equal levels of inhibition but to produce
detectable diﬀerences in phosphorylation between stimulated
and inhibited states using at least two known inhibitors of
EGFR. The amount of receptor phosphorylation at sites Y998
and Y1172 in A431 cells (Figure 5) was signiﬁcantly elevated in
EGF treated samples over proliferating controls. As expected,
both cetuximab and geﬁtinib inhibitor treatments decreased the
amount of tyrosine phosphorylation detected when compared
to EGF treatment alone. The EGFR tyrosine kinase inhibitor
geﬁtinib at 500 nM decreased tyrosine phosphorylation below
basal levels at both sites, whereas at a dose of 10 μgm L −1,
cetuximab was not as eﬀective at inhibiting EGFR phosphor-
ylation.
For quantitative LC−MS/MS experiments, EGFR was
immunoprecipitated from the A431 cells with cetuximab in
the presence of protease and phosphatase inhibitors, separated
Table 1. Phosphopeptides and Corresponding Reference Peptides Used for Normalization: r2 Value, Slope, and CV Are
Calculated for Five Technical Replicates
Journal of Proteome Research Technical Note
dx.doi.org/10.1021/pr201240a | J. Proteome Res. 2012, 11, 3467−3479 3472on an SDS-PAGE gel, and the EGFR band was excised and
digested in-gel with trypsin (Figure 4). Modiﬁed peptides
corresponding to phosphorylation at sites Y998
(MHLPSPTDSNFpYR), Y1110 (RPAGSVQNPV-
pYHNQPLNPAPSR), Y1172 (GSHQISLDNPD-
pYQQDFFPK), Y1197 (GSTAENAEpYLR), S991
(MHLPpSPTDSNFYR), and S1166 (GSHQIpSLDNP-
DYQQDFFPK) within EGFR were targeted for quantiﬁcation
using pSRM. Figure 6 shows the extracted ion chromatograms
using Skyline for Y1197 for each treatment type. Phosphoserine
sites (S991 and S1166) also were monitored using MS3 of the
98 Da neutral loss ion corresponding to the neutral loss of
phosphoric acid. Stable isotope-labeled peptides corresponding
to sites Y998, Y1110, Y1172, and Y1197 were spiked in prior to
pSRM analysis to permit comparison of the IRP and SID
methods for quantitation. Five unmodiﬁed peptides from
EGFR were selected for normalization using the IRP method.
The location and domain position (extracellular, juxtamem-
brane, tyrosine kinase or cytoplasmic) of each reference and
phosphorylated peptide in EGFR is presented in Figure S11
(Supporting Information). Internal reference peptides were
selected based on high signal stability and a wide range of
elution times (see Figure S12, Supporting Information). For
each targeted peptide monitored, XICs were selected for three
to ﬁve transitions that indicate modiﬁcation speciﬁcity (when
possible) and that generated strong pSRM transitions signals.
Although modiﬁcation site-speciﬁc transitions do not always
produce suﬃcient signal for quantitation, they frequently can be
used to verify the site of modiﬁcation. In the case of Y998 vs
S991 phosphorylation, we were able to verify the site not only
with modiﬁcation site-speciﬁc fragment ions but also with the
comparison to the Y998 phosphorylated synthetic peptide.
Extracted ion chromatograms for peptides Y998 and S991
(MHLPSPTDSNFpYRa n dM H L P pSPTDSNFYR, respec-
tively; shown in Figure S2, Supporting Information) demon-
strate baseline separation of these species under our
experimental conditions. Since only one or two modiﬁcation
site-speciﬁc transitions were detected, these ions were used
primarily to distinguish the two distinct phosphorylated peptide
signals. We utilized a few nonspeciﬁc transitions for
quantitation since baseline separation was achieved. It is
possible that the digestion of this peptide may be hindered
when the tyrosine is phosphorylated (given its proximity to the
tryptic cleavage site); we assumed that the relative amounts of
both peptides (MHLPSPTDSNFpYRa n d
MHLPpSPTDSNFYR) with respect to treatment should
remain unaﬀected and digestion should be reproducible, thus
the conclusion is the same. We believe that this assumption is
reasonable since we are not comparing the absolute amount of
these two peptides and our data was consistent among the
three biological replicates. The absolute amount of the Y998
peptide estimated by SID, however, may be aﬀected by this
potential for missed cleavage. The peptide sequences, precursor
m/z, and speciﬁc transitions are listed in Table S13, Supporting
Information. Peak areas were calculated from the sum of
transitions for the phosphopeptides and then divided by the
Figure 4. (A) Illustration of the immunoprecipitation (IP) method for EGFR and treatment groups utilized in these experiments. After IP, the EGFR
corresponding band on SDS PAGE gel was excised and targeted analysis performed on an LTQ Velos mass spectrometer. (B) Representation of the
analytical approach for normalizing six EGFR phosphorylated peptides to internal reference peptides (IRPs). IRPs are unmodiﬁed peptides within
the protein of interest, in these experiments, EGFR.
Figure 5. A431 cells untreated, modulated with EGF, or cotreated with
inhibitor (cetuximab or geﬁtinib) followed by EGF exhibit diﬀerent
EGFR activation statuses. Immunoblot showing EGFR activation prior
to and after treatment(s) (phosphorylation at Y998 and Y1172). Both
phosphorylated forms of the receptor were targeted in the pSRM-MS
method. Input lane is 5% of total protein load, and IP lane is post-
immunoprecipitation. Control lanes show the IP performed using
mouse IgG. All treated cells were serum-starved overnight prior to any
treatment.
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stable isotope-labeled standards (for SID). Three biological
replicates were performed for each treatment group and three
LC−pSRM−MS injections for each sample.
To evaluate the performance of the IRP method, we
compared CV values for measurements using diﬀerent IRP
peptides together with SID analyses for each of the six EGFR
phosphorylation sites analyzed (Table 2). Plots of CVs for
technical replicate analyses from each of three biological
replicate experiments are presented in Figures S14−S19
(Supporting Information). Median CV values varied consid-
erably for IRP measurements with diﬀerent normalization
peptides. Normalization to the EGFR peptide IPLENLQIIR
yielded the lowest global CV (median 22%), whereas the other
normalization peptides NLQEILHGAVR (median 27%),
EISDGDVIISGNK (median 27%), GLWIPEGEK (median
26%), and ITDFGLAK (median 32%) displayed modestly
greater variation. CV values diﬀered between distinct biological
replicate experiments. In our studies, biological replicate
experiments 1 and 2 displayed lower variability, with median
CVs from diﬀerent IRP peptides averaging approximately 30%,
whereas biological replicate experiment 3 yielded more
variation. This higher variation was caused by individual
technical replicate runs (individual injections on the mass
spectrometer using the same sample), some of which produced
low signal across the chromatogram. Because these pSRM
analyses employed ion trap analyzers, we were able to compare
ion injection times for low-signal versus high-signal runs.
Technical replicate runs with low-signal displayed considerably
longer ion injection times and correspondingly low signal for
summed MRM transitions (compare Figures S20−21 (low-
signal run) with Figures S22−23 (high-signal run), Supporting
Information. This phenomenon was most likely due to
instrumental issue, such as an incomplete injection or some
other signal failure in the mass spectrometer. In all of the
experiments, the SID method yielded signiﬁcantly greater
measurement precision with a global median CV of 15%.
The data generated by analyses of immunoprecipitated
EGFR from biological experiment 1 by the IRP and SID
methods are shown in Figure 7. Both methods yielded similar
measures of phosphorylation at Y1172 (GSHQISLDNPD-
pYQQDFFPK), its stimulation by EGF, and inhibition by
cetuximab and geﬁtinib (Figure 7A,B). The IRP method
produced similar results to SID for all four phosphotyrosine
sites (Y998, Y1110, Y1172, and Y1197) (Figure 7C and Figures
S24−S27, Supporting Information). These results are also
consistent with the immunoblot analysis for Y1172 shown in
Figure 5. EGF-treated stimulation produced the highest
normalized pSRM signal, whereas samples cotreated with 500
nM geﬁtinib showed profound decreases in Y1172 phosphor-
ylation to below basal (proliferating) levels. Co-treatment with
cetuximab produced less inhibition in Y1172 phosphorylation
to near basal levels. Figure 7C represents the degree of site-
speciﬁc phosphorylation relative to that for EGF stimulation by
a phosphorylation index, which was calculated as the ratio of
the proliferating (P), geﬁtinib (G+E), or cetuximab (C+E)
Table 2. Phosphopeptides and Corresponding Reference Peptides Used for Normalization−CV Range and Median CV Is
Calculated Across Technical Replicates (Three Total) for Each Treatment
a
aThis data encompasses all three biological replicates. The underlined amino acid indicates which amino acid was stable isotope-labeled.
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pSRM signal (eq 1). Although we monitored the corresponding
peptides without phosphorylation (data not shown), we did not
see any appreciable changes in the quantitation of these
peptides, most likely due to the low stoichiometry of the
phosphorylation (data not shown).
=
++
×
phosphorylation index
normalized pSRM signal of P, G E or C E
normalized pSRM signal of EGF
100
(1)
Both IRP (IPLENLQIIR) and SID methods yielded similar
results and consistently detected similar phosphorylation status
diﬀerences among the four treatment groups.
Analysis of EGFR Phosphoserine Modiﬁcations Using MS3
Measurements
For pS and pT peptides whose MS/MS spectra are dominated
by neutral loss of H3PO4, measurements based on MS3
fragmentation of the neutral loss ion may oﬀer higher
conﬁdence sequence-speciﬁc detection. MS3 measurements
for relative quantiﬁcation of phosphoserine modiﬁcations were
performed on peptides for EGFR sites S991
(MHLPpSPTDSNFYR) [M + 2H − H3PO4]2+ and S1166
(GSHQIpSLDNPDYQQDFFPK) [M + 3H − H3PO4]3+. Peak
areas from MS3 measurements were normalized to MS/MS-
derived peak areas for the 5 EGFR IRP sequences described
above, as well as to the MS/MS-derived peak areas for the
isotope-labeled pY peptide standards used for SID analyses of
the pY forms of these sequences (see above). Median CV plots
using the IRP method for S991 and S1166 phosphopeptides
(Figures S18 and S19, Supporting Information) indicate that
normalization to the IPLENLQIIR peptide produced the
smallest measurement variation, which was comparable to
that achieved with normalization to the synthetic pY SID
peptide sequence analogs. Both analysis methods yielded
similar estimates of phosphorylation changes induced by EGF
and the eﬀects of cetuximab and geﬁtinib (Figure 8 and Figures
S28 and S29, Supporting Information).
Phosphorylation levels for S991 display a pattern similar to
that for the four phosphotyrosines described above. Phosphor-
ylation at S991 increased after EGF treatment compared to
basal (proliferating) levels and were reversed, although not
completely, by both inhibitors. This result diﬀers somewhat
from the near complete reversal of phosphotyrosine mod-
iﬁcation we observed above for geﬁtinib. Similar results for
S991 phosphorylation were reported by Stover et al.,
26 who
used mass spectrometry analyses to detect S991 phosphor-
ylation induced by EGF stimulation and inhibited by the EGFR
inhibitor PK166.
Figure 7. Treatment groups show the same trends when pY peptides are normalized to an internal reference peptide or its stable isotope labeled
counterpart. EGFR peptide pY1172 (GSHQISLDNPDpYQQDFFPK) normalized to an (A) internal reference peptide (IPLENLQIIR) and (B) its
pY SID peptide standard. (C) Phosphorylation index for each EGFR pY peptide and cell treatment group. Similar trends are observed for each pY
targeted peptide after normalization to an IRP (red) or its stable isotope labeled counterpart (purple). The phosphorylation index is normalized to
EGF (100%) stimulated cells. These data represent three technical LC−pSRM−MS injections of biological replicate 1. ND, not detected in LC−
pSRM−MS experiments. The underlined amino acid indicates which amino acid was stable isotope-labeled. For biological replicate 1, CV values
ranged between 9.8−47% and 7.3−32% for the IRP and SID method, respectively. The higher CV values were generated from Geftinib + EGF
samples, and the median CV values ranged were 21% and 24%, respectively.
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(GSHQIpSLDNPDYQQDFFPK) using both methods indi-
cated a very diﬀerent pattern. EGF treatment produced little or
no S1166 phosphorylation, although geﬁtinib further decreased
phosphorylation at this site. The lack of signiﬁcant EGF-
induced phosphorylation at S1166 is consistent with a previous
study that employed a mass spectrometry method.
16 On the
other hand, combined cetuximab and EGF produced the
highest amount of phosphorylation at S1166.
■ DISCUSSION
Our major goal in this work was to evaluate the IRP method for
quantifying changes in protein PTM and to demonstrate the
utility of pSRM for quantiﬁcation. Although we have previously
reported a similar approach,
22,23 we describe here the
performance characteristics of the method in comparison to
SID. We further describe the implementation of MS/MS and
MS3-based pSRM measurements on an LTQ Velos ion trap
instrument. The pSRM transitions can be extracted from MS/
MS and MS3 data, normalized to peak areas from reference
peptides within the same protein, thus aﬀording relative
quantiﬁcation of protein modiﬁcations. Unlike MRM data,
pSRM data records a full MS/MS spectrum for each monitored
peptide, which allows for spectrum veriﬁcation by visual
inspection as well as the ability to choose diﬀerent ions to
extract based on PTM site (e.g., pS, pT vs pY) (see Figure 2 and
Figures S1 and S2, Supporting Information). As with other MS-
based methods, the IRP method can measure multiple site-
speciﬁc phosphorylation sites in parallel without the need for
site-speciﬁc antibodies and without potential concerns about
antibody cross-reactivity and lack of phospho-site speciﬁcity.
Although the method lacks the analytical precision of SID, the
needless requirement for labeled internal standards, the ease of
implementation and the suitability for typical quantitative
comparisons, as illustrated with our analyses of EGFR
phosphorylation, make this method suitable for broad
application in protein biochemistry.
Previous label-free quantitation approaches have utilized
estimated stoichiometry (ES), ﬂyability ratios, the native
reference peptide (NRP) method or the selected ion tracing
method to quantify post-translational modiﬁcations.
12,16−21 In
all of these methods, XICs (ion currents) at the MS1 level are
generated for each site speciﬁc modiﬁcation as well as its
unmodiﬁed peptide complement or an unmodiﬁed reference
peptide. These methods calculate the stoichiometry (or site
abundance) of individual post-translationally modiﬁed sites by
taking the modiﬁed peptide peak area and normalizing to the
sum of modiﬁed and unmodiﬁed peak area,
21 to an unmodiﬁed
reference peptide peak area
18−20 or to the sum of unmodiﬁed
peak area plus the peak area of any other possible sites of
modiﬁcation on the target peptide.
16 A key diﬀerence between
our approach and previous methods is the use of MS/MS
extracted ion chromatograms rather than MS1 data for each
modiﬁed and reference peptide. Unlike the ES method and
Figure 8. MS3 trend plots for two phosphoserine modiﬁed peptides based on treatment group. Phosphopeptide pS991 (MHLPpSPTDSNFYR)
normalized to an (A) IRP or (B) pY SID peptide standard (MHLPSPTDSNFpYR) shows similar trends. These data are similar to trends observed
for pY peptide MHLPSPTDSNFpYR. Phosphopeptide pS1166 (GSHQIpSLDNPDYQQDFFPK) normalized to an (C) IRP or (D) pY SID peptide
standard (GSHQISLDNPDpYQQDFFPK) show similar trends. These data show that MS3 measurements can be used for quantiﬁcation of protein
modiﬁcations. These data represent three technical injects of biological replicate 2. The underlined amino acid indicates which amino acid was stable-
isotope labeled.
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data to obtain peptide sequence and site speciﬁc localization
data, thus allowing not only veriﬁcation of the site of
modiﬁcation but also site-speciﬁc quantitation even when
peptide peaks cannot be resolved (see Figure 2 and Figure S1,
Supporting Information).
Our initial proof-of-principle experiment analyzed two
phosphopeptides spiked at increasing concentrations into a
BSA digest. The simulated IRP method by pSRM achieved a
linear response on the LTQ Velos ion-trap mass spectrometer
across 2 orders of magnitude for all normalization peptides
examined (Figure S3, Supporting Information). Some normal-
izing peptides produced a more consistent response, which
correlated to lower variability (<10% CV, see Table 1).
Although the higher end of the standard curve may exceed the
concentration of modiﬁed peptide that would typically occur in
a protein, we examined higher concentrations to determine
whether the automatic gain control (AGC) aﬀected linearity of
response. Even at higher concentrations, where ion injection
times were shortened by AGC (to limit the ions according to
the set target intensity value), the detected response remained
linear (see r2 values in Table 1) using these instrument settings.
As expected, lower phosphopeptide concentrations yielded
greater measurement variability, as indicated by higher median
CV measurements (>30% median CV for 0.13 fmol (0.01 fmol
ng−1 of BSA) phosphopeptide (Figure 3). Higher CV values are
typical for peptide concentrations at or near the limit of
detection due to the decreased signal-to-noise that is typically
observed. It should be noted in these types of experiments
there needs to be a balance between the approapriate maximum
target intensity value and the ion injection time settings for
AGC. We observed linearity in our proof-of-principle experi-
ment despite a nearly 1000-fold diﬀerence between the
reference peptide and modiﬁed peptide concentrations (lowest
point modeled 0.12% stoichiometry). Large diﬀerences in signal
intensities of the reference peptides and modiﬁed peptides may
still create nonlinearity and space charging in ion traps may also
aﬀect quantitation, so this should be considered in instrument
acquisition settings. Median CVs showed lower variations
(≤20%) as phosphopeptide analyte concentration increased
from 0.13 to 25.6 fmol (0.01 fmol ng−1 of BSA up to 2.00 fmol
ng−1 of BSA) (Figure 3). Elevated CVs for both SID and IRP
methods also were obtained in geﬁtinib- and EGF-treated
samples, which typically had low levels of phosphorylated
peptides and where signals approached the limit of detection
(Figures S14−S19, Supporting Information).
In the BSA spike model, standard curves for the pS peptide
IKNLQpSLDPSH (MS3 data) had r2 values, slopes, and CVs
similar to or better than those obtained from MS/MS data
when using the same normalizing peptide (Table 1). Although
ion intensity for the MS3 spectra were approximately 10-fold
lower than the MS/MS data, the MS3 data typically had better
signal-to-noise ratios and thus similar or better CVs. MS3 data
thus can be used for relative quantiﬁcation of protein
modiﬁcations, especially when MS/MS data of pS or pT
containing peptides do not provide adequate fragment ion data
for site-speciﬁc modiﬁcation mapping or sequence determi-
nation. Higher order tandem MS experiments such as the MS3
measurements demonstrated here cannot be obtained in
quadrupole mass analyzers traditionally used for quantiﬁcation,
but can be performed on ion trap instruments.
In the EGFR phosphorylation studies, internal reference
peptides were chosen such that (1) they were known to be
unmodiﬁed, (2) eluted across the chromatogram, (3) displayed
consistent signal stability, (4) were observed in previous data
dependent LC-MS/MS data, and (5) contained between 7 and
20 amino acids and preferably lacked methionine and cysteine
residues. In these studies, we did not identify any other
measures (e.g., location in LC elution time, similarity in peptide
length/sequence, etc.) to predict the best IRP to use.
Phosphopeptides were normalized individually to the each of
the ﬁve internal reference peptides (ITDFGLAK, IPLENL-
QIIR, GLWIPEGEK, NLQEILHGAVR, and EISDGD-
VIISGNK). Individual analyses of the internal reference
peptides indicated that some internal reference peptides
showed large diﬀerences in the range and median CV plots
(Figures S14−S19, Supporting Information). Our results show
that multiple IRPs should be evaluated to optimize the
performance of the IRP method and to ensure that any given
reference peptide does not conﬂict with the results of the
others. Ultimately, we chose the internal reference peptide with
the lowest median CV (highest signal stability) in the data set,
unless there were clear contradictory results to the other
reference peptides (as was the case for the GLWIPEGEK
reference peptide described below).
We studied biological variations of EGFR phosphorylation in
A431 cells under four treatment conditions. Analyses with the
IRP method using all internal reference peptides (except
GLWIPEGEK) detected the same diﬀerences between treat-
ments as did SID analyses. This demonstrates that moderate
diﬀerences in measurement variation do not signiﬁcantly
impact the biological conclusions drawn from these studies.
In our SID analysis of 4 analyzed phosphotyrosine sites in
EGFR, median CVs ranged from 5 to 15%, whereas analyses
with the IRP method (using reference peptide IPLENLQIIR)
of the same four sites had median CVs around 20% (Figures
S14−S19, Supporting Information). Although the median CV
for the IRP method was greater than the SID method, the
interpretation of phosphorylation diﬀerences with both
methods is the same. We also monitored phosphorylation
sites Y998 and Y1172 with commercially available antibodies
and these analyses conﬁrmed the mass spectrometry results
(Figure 5). By all three methods (immunoblot, SID and IRP),
geﬁtinib was a more potent inhibitor of EGFR than cetuximab
at indicated concentrations; immunoblot analyses for Y998 and
Y1172 were barely above background and both SID and IRP
methods for sites Y998, Y1110, Y1172, and Y1197 were
calculated to have a phosphorylation index <10% when
compared to EGF treated cells. The corresponding non-
phosphorylated peptides did not appear to signiﬁcantly change
in response to treatment. This is most likely due to the very low
stoichiometry of these phosphorylations, consistent with
previous studies.
12
Analysis using MS3 spectra for two pS containing peptides in
EGFR, MHLPpSPTDSNFYR (S991), and GSHQIpSLDNP-
DYQQDFFPK (S1166) yielded results consistent with
previous literature reports.
16,26 Phosphoserine peptide S991
follows the same overall changes as the four EGFR pY sites
(Y998, Y1110, Y1172, and Y1197); with the exception that
geﬁtinib was not a more potent inhibitor than cetuximab (i.e.,
at the concentrations used geﬁtinib and cetuximab have similar
inhibitory eﬀects on S991). Trends across the diﬀerent
treatment groups were consistent whether the MS3 pS peptides
were normalized to the isotope-labeled pY SID peptide
standard or to the internal reference peptide with the lowest
median CV (IPLENLQIIR). The eﬀect of EGFR inhibitors on
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In these experiments, the SID and IRP methods were
analyzed on a linear ion trap mass spectrometer (LTQ Velos),
which can monitor ≤20 peptides in a single LC−pSRM−-MS
experiment. While pSRM measurements do not provide the
same throughput as triple quadrupole based MRM analyses
(>30 peptides can be measured with four transitions in a single,
unscheduled LC−triple quadrupole MRM analysis), the added
beneﬁt of the peptide sequence conﬁrmation from the full MS/
MS spectrum and the ability to acquire higher order tandem
MS data are signiﬁcant advantages. The pSRM approach also
allows selection of the transition after MS/MS analysis as well
as quantitation using fragment ions when MS1 data is poor (see
Figure 2). Having the tandem MS spectrum enables
quantitative extension of modiﬁcation mapping experiments
without transferring methods to another platform. Our results
suggest several precautions that can improve the reliability of
pSRM analyses. First, multiple technical replicate injections
enable assessment of instrument performance-based variation
due to chromatography, detectors, ion injection times, and
signal intensity. Second, an IRP method should incorporate
multiple internal reference peptides to provide conﬁrmatory
results, to identify peptides with the lowest variation and to
minimize error due to ion suppression eﬀects, and coeluting
interferences. In our studies, we observed a consistently poor
performing internal reference peptide, GLWIPEGEK, which
generated large variations in CV for normalized pSRM signal
(Figures S14−S19, Supporting Information) and also generated
EGF- and inhibitor-related phosphorylation diﬀerences incon-
sistent with analyses using the other internal reference peptides
(i.e., S1166, see Figure S29, Supporting Information). The
GLWIPEGEK internal reference peptide may perform poorly
due to inconsistent digestion resulting in a C-terminal missed
cleavage (see Figure S11, Supporting Information) or due to
some interfering ions of similar m/z adding to the noise of the
signal or causing signal suppression. If the inconsistency is due
to similar m/z adding to the noise, this could potentially be
resolved using a higher resolution instrument for this approach.
Arbitrary selection of a single reference peptide would not have
detected this poor perfoming peptide. Theoretical prediction of
optimal internal reference peptides may not be adequate and
may require the examination of multiple internal reference
peptide signals in a biological matrix to ensure consistency.
We employ the IRP method for analyses of modiﬁcations on
individual proteins in relatively simple samples, such as
immunoprecipitated proteins or proteins isolated from SDS−
PAGE gel bands. We have not considered and do not
recommend the IRP method for global analyses of modiﬁed
proteins in complex proteomes. In the appropriate context, the
IRP method is intended to estimate diﬀerences in protein
modiﬁcations between similar samples. The data are com-
parable in measurement variation to immunoblot analyses (CVs
up to 40%). MS-based analyses, such as the IRP and SID
methods, are able to selectively measure many site-speciﬁc
changes for which reliable antibody reagents are unavailable.
The IRP method displays lower precision than SID, but it is
useful in many applications where high precision is not
required. IRP-based methods also do not use labeled peptide
standards, which signiﬁcantly increases analysis costs. In the
context of targeted biochemical analyses, the IRP method
accounts for variations in immunoprecipitation or aﬃnity
capture eﬃciency and gel fractionation. By utilizing multiple
peptides for normalization, we account for variable digestion or
other unknown modiﬁcation of the normalization peptides. The
IRP method also accounts for variability in both biological and
technical replicates. These features make the IRP method a
ﬂexible, general approach for comparative analysis of protein
modiﬁcations which can ﬁnd widespread application in
biochemical analyses.
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